MaaT Pharma: ambitious?




By




MaaT Pharma climbs 2.6% to 7.80 euros, as the advanced clinical stage biotechnology company, leader in the development of Microbiome Ecosystem Therapies (MET) aimed at improving the survival of patients with cancer, announces that the first patient was treated as part of its…

This stock market news is reserved for subscribers Privileges


Test our stock market advice for €1, without obligation


I subscribe

Already subscribed? Log in

Discover Boursier.com services Privileges


  • 8:30 a.m.
    Today’s recce

  • 4 to 5 stock market tips per day


    4 to 5 tips
    scholarship holders per day

  • weekly letter “Opportunities”


    Weekly letter “Opportunities”



  • Wallets
    defensive, balanced
    and dynamic


Learn more


©2023 Boursier.com



Source link -87